Massimo A. Cristofanilli

Oncology

1283 York Ave Fl 4
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 320 publications

Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.

Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.

Journal: Current opinion in oncology

Published: September 03, 2026

Attention U-Net-Based Segmentation and Hybrid Classification for Detection of Circulating Tumor-Associated Cells.

Attention U-Net-Based Segmentation and Hybrid Classification for Detection of Circulating Tumor-Associated Cells.

Journal: Cancers

Published: July 17, 2026

Improved Surfactant-Assisted One-Pot Sample Preparation for Robust Convenient Single-Cell Proteomics.

Improved Surfactant-Assisted One-Pot Sample Preparation for Robust Convenient Single-Cell Proteomics.

Journal: Journal of proteome research

Published: July 10, 2026

Bioinformatics of Shallow Whole Genome Sequencing Data of Circulating Tumor Cells to Inform Cancer Diagnosis and Treatment.

Bioinformatics of Shallow Whole Genome Sequencing Data of Circulating Tumor Cells to Inform Cancer Diagnosis and Treatment.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 09, 2026

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2026

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 24, 2026

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.

Journal: Cancer

Published: March 30, 2026

Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value.

Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value.

Journal: Science translational medicine

Published: March 11, 2026

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

Journal: NPJ breast cancer

Published: March 09, 2026

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 09, 2026

Showing 1-12 of 320

Last Updated: 09/26/2026